Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline

Neurobiology of Aging

Volumn 33, Issue 7, 2012, Pages 1129-1137

  Kang, Jae H ^a   Grodstein, Francine ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cognitive aging; Cohort studies; MCI; Memory; Risk factors in epidemiology

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; PIPERAZINE ESTRONE SULFATE;

ADULT; AGED; ALLELE; APOE GENE; ARTICLE; CLINICAL ASSESSMENT; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE; GENE FUNCTION; GENERAL CONDITION DETERIORATION; GENOTYPE; HETEROZYGOTE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MEMORY DISORDER; MENOPAUSAL SYNDROME; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RISK FACTOR; VERBAL MEMORY;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN E4; COGNITION DISORDERS; DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSTMENOPAUSE; QUESTIONNAIRES; TIME FACTORS;

EID: 84861200545     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.10.007     Document Type: Article

References (46)

1. Albert M., Smith L.A., Scherr P.A., Taylor J.O., Evans D.A., Funkenstein H.H. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int. J. Neurosci 1991, 57:167-178.
2. Almeida O.P., Lautenschlager N.T., Vasikaran S., Leedman P., Gelavis A., Flicker L. A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life. Neurobiol. Aging 2006, 27:141-149.
3. Bennett D.A., Wilson R.S., Schneider J.A., Evans D.A., Beckett L.A., Aggarwal N.T., Barnes L.L., Fox J.H., Bach J. Natural history of mild cognitive impairment in older persons. Neurology 2002, 59:198-205.
4. Brandt J., Spencer M., Folstein M. The telephone interview for cognitive status. Neuropsychiatry Neuropsychol. Behav. Neurol 1988, 1:111-117.
5. Bretsky P., Guralnik J.M., Launer L., Albert M., Seeman T.E. The role of APOE-e4 in longitudinal cognitive decline. Neurology 2003, 60:1077-1081.
6. Carlson M.C., Zandi P.P., Plassman B.L., Tschanz J.T., Welsh-Bohmer K.A., Steffens D.C., Bastian L.A., Mehta K.M., Breitner J.C.S. Hormone replacement therapy and reduced cognitive decline in older women: The Cache County Study. Neurology 2001, 57:2210-2216.
7. Colditz G.A., Stampfer M.J., Willett W.C., Stason W.B., Rosner B., Hennekens C.H., Speizer F.E. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am. J. Epidemiol 1987, 126:319-325.
8. Cushman M., Legault C., Barrett-Connor E., Stefanick M.L., Kessler C., Judd H.L., Sakkinen P.A., Tracy R.P. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999, 100:717-722.
9. den Heijer T., Geerlings M.I., Hofman A., de Jong F.H., Launer L.J., Pols H.A., Breteler M.M. Higher estrogen levels are not associated with larger hippocampi and better memory performance. Arch. Neurol 2003, 60:213-220.
10. Espeland M.A., Rapp S.R., Shumaker S.A., Brunner R., Manson J.E., Sherwin B.B., Hsia J., Margolis K.L., Hogan P.E., Wallace R., Dailey M., Freeman R., Hays J. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004, 291:2959-2968.
11. Fillenbaum G.G., Hanlon J.T., Landerman L.R., Schmader K.E. Impact of estrogen use on decline in cognitive function in a representative sample of older community-resident women. Am. J. Epidemiol 2001, 153:137-144.
12. Fillit H.M. The role of hormone replacement therapy in the prevention of Alzheimer disease. Arch. Intern. Med 2002, 162:1934-1942.
13. Fitzmaurice G.M., Laird N.M., Ware J.H. Modelling the mean: analyzing response profiles. Applied Longitudinal Analysis 1934, 103-139. John Wiley & Sons, Inc, Hoboken, NJ.
14. Gibbs R.B., Gabor R. Estrogen and cognition: applying preclinical findings to clinical perspectives. J. Neurosci. Res 2003, 74:637-643.
15. Grodstein F., Clarkson T.B., Manson J.E. Understanding the divergent data on postmenopausal hormone therapy. N. Engl. J. Med 2003, 348:645-650.
16. Grodstein F., Kang J.H., Glynn R.J., Cook N.R., Gaziano J.M. A randomized trial of beta-carotene supplementation and cognitive function in men: The Physicians' Health Study II. Arch. Intern. Med 2007, 167:2184-2190.
17. Grodstein F., Manson J.E., Stampfer M.J., Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch. Intern. Med 2008, 168:861-866.
18. Henderson V.W. Oestrogens and dementia. Novartis Foundation Symposium 2000, 230:254-265.
19. Kang J.H., Weuve J., Grodstein F. Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women. Neurology 2004, 63:101-107.
20. Lethaby A., Hogervorst E., Richards M., Yesufu A., Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst. Rev 2008, CD003122.
21. MacLennan A.H., Henderson V.W., Paine B.J., Mathias J., Ramsay E.N., Ryan P., Stocks N.P., Taylor A.W. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause 2006, 13:28-36.
22. MacLusky N.J. Estrogen and Alzheimer's disease: the apolipoprotein connection. Endocrinology 2004, 145:3062-3064.
23. Maki P.M., Sundermann E. Hormone therapy and cognitive function. Hum. Reprod. Update 2009, 15:667-681.
24. Markowska A.L., Savonenko A.V. Effectiveness of estrogen replacement in restoration of cognitive function after long-term estrogen withdrawal in aging rats. J. Neurosci 2002, 22:10985-10995.
25. Nathan B.P., Barsukova A.G., Shen F., McAsey M., Struble R.G. Estrogen facilitates neurite extension via apolipoprotein E in cultured adult mouse cortical neurons. Endocrinology 2004, 145:3065-3073.
26. Pefanco M.A., Kenny A.M., Kaplan R.F., Kuchel G., Walsh S., Kleppinger A., Prestwood K. The effect of 3-year treatment with 0.25 mg/day of micronized 17beta-estradiol on cognitive function in older postmenopausal women. J. Am. Geriatr. Soc. 2007, 55:426-431.
27. Petitti D.B., Crooks V.C., Chiu V., Buckwalter J.G., Chui H.C. Incidence of dementia in long-term hormone users. Am. J. Epidemiol 2008, 167:692-700.
28. Prentice R.L., Manson J.E., Langer R.D., Anderson G.L., Pettinger M., Jackson R.D., Johnson K.C., Kuller L.H., Lane D.S., Wactawski-Wende J., Brzyski R., Allison M., Ockene J., Sarto G., Rossouw J.E. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am. J. Epidemiol 2009, 170:12-23.
29. Raber J., Wong D., Buttini M., Orth M., Bellosta S., Pitas R.E., Mahley R.W., Mucke L. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:10914-10919.
30. Rapp S.R., Espeland M.A., Shumaker S.A., Henderson V.W., Brunner R.L., Manson J.E., Gass M.L.S., Stefanick M.L., Lane D.S., Hays J., Johnson K.C., Coker L.H., Dailey M., Bowen D. Effect of estrogen plus progestin on global cognitive function in postmenopausal women; the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2663-2672. WHIMS Investigators.
31. Resnick S.M., Espeland M.A., An Y., Maki P.M., Coker L.H., Jackson R., Stefanick M.L., Wallace R., Rapp S.R. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. J. Clin. Endocrinol. Metab 2009, 94:4152-4161.
32. Resnick S.M., Espeland M.A., Jaramillo S.A., Hirsch C., Stefanick M.L., Murray A.M., Ockene J., Davatzikos C. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology 2009, 72:135-142.
33. Resnick S.M., Maki P.M., Rapp S.R., Espeland M.A., Brunner R., Coker L.H., Granek I.A., Hogan P., Ockene J.K., Shumaker S.A. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J. Clin. Endocrinol. Metab 2006, 91:1802-1810.
34. Sherwin B.B. Estrogen and cognitive functioning in women. Endocr. Rev 2003, 24:133-151.
35. Shumaker S.A., Legault C., Kuller L., Rapp S.R., Thal L., Lane D.S., Fillit H., Stefanick M.L., Hendrix S.L., Lewis C.E., Masaki K., Coker L.H. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004, 291:2947-2958.
36. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., Hendrix S.L., Jones B.N., Assaf A.R., Jackson R.D., Kotchen J.M., Wassertheil-Smoller S., Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women; the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2651-2662. WHIMS Investigators.
37. Stone D.J., Rozovsky I., Morgan T.E., Anderson C.P., Finch C.E. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. J. Neurosci 1998, 18:3180-3185.
38. Struble R.G., Cady C., Nathan B.P., McAsey M. Apolipoprotein E may be a critical factor in hormone therapy neuroprotection. Front. Biosci 2008, 13:5387-5405.
39. Viscoli C.M., Brass L.M., Kernan W.N., Sarrel P.M., Suissa S., Horwitz R.I. Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST). Am. J. Obstet. Gynecol 2005, 192:387-393.
40. Wassertheil-Smoller S., Hendrix S., Limacher M., Heiss G., Kooperberg C., Baird A., Kotchen T., Curb J.D., Black H., Rossouw J.E., Aragaki A., Safford M., Stein E., Laowattana S., Mysiw W.J. Effect of estrogen plus progestin on stroke in postmenopausal women; the Women's Health Initiative: a randomized trial. JAMA 2003, 289:2673-2684. WHI Investigators.
41. Welsh K.A., Butters N., Mohs R.C. The Consortium To Establish a Registry for Alzheimer's Disease (CERAD). Neurology 1994, 44:609-614.
42. Willett W.C., Stampfer M.J., Bain C., Lipnick R., Speizer F.E., Rosner B., Cramer D., Hennekens C.H. Cigarette smoking, relative weight, and menopause. Am. J. Epidemiol 1983, 117:651-658.
43. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333. Writing Group for the Women's Health Initiative Investigators.
44. Yaffe K., Haan M., Byers A., Tangen C., Kuller L. Estrogen use, APOE, and cognitive decline: Evidence of a gene-environment interaction. Neurology 2000, 54:1949-1953.
45. Yaffe K., Vittinghoff E., Ensrud K.E., Johnson K.C., Diem S., Hanes V., Grady D. Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life. Arch. Neurol 2006, 63:945-950.
46. Zandi P.P., Carlson M.C., Plassman B.L., Welsh-Bohmer K.A., Mayer L.S., Steffens D.C., Breitner J.C.S. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002, 288:2123-2129.